Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results